ArticleAIDS (London, England)2021
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV.
Article in AIDS (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Low SARS-CoV-2 Positivity in a Large, Diverse US-Based Study of Persons Affected by HIV.AIDS and behavior · 2026Article
- HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative.Open forum infectious diseases · 2026Article
- SARS-CoV-2 Infection, Hospitalization, and Associated Factors Among People Living With HIV in Southeastern China From December 2022 to February 2023: Cross-Sectional Survey.JMIR public health and surveillance · 2024Article
- Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA).PloS one · 2024Article
- Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity.The Journal of infectious diseases · 2023Article
- COVID-19 as a catalyst for vaccine manufacturing: A South African experience.Cell host & microbe · 2023Article
- Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV.JCI insight · 2023 · on this mapArticle
- Stress, Support, and Length of Diagnosis Among Women Living with HIV/AIDS in the Southern USA, During the COVID-19 Pandemic.HIV/AIDS (Auckland, N.Z.) · 2023Review
- Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.Frontiers in immunology · 2023Article
- COVID-19 Outcomes and Risk Factors Among People Living with HIV.Current HIV/AIDS reports · 2022Review
- COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus.Infectious disease clinics of North America · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
To assess SARS-CoV-2 outcomes, we matched a municipal COVID-19 registry and clinic rosters from a municipal primary care network containing a large HIV clinic and assessed clinical outcomes by HIV status. The risk of severe COVID-19 was higher among people with HIV (PWH, adjusted relative risk = 1.84, 95% confidence interval = 1.05-3.25), while SARS-CoV-2 incidence was lower despite higher testing rates. SARS-CoV-2 vaccination campaigns should prioritize PWH to prevent severe COVID-19 disease given potentially higher risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.